[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HN2003000196A - Derivados de indolinfenilsulfonamida - Google Patents

Derivados de indolinfenilsulfonamida

Info

Publication number
HN2003000196A
HN2003000196A HN2003000196A HN2003000196A HN2003000196A HN 2003000196 A HN2003000196 A HN 2003000196A HN 2003000196 A HN2003000196 A HN 2003000196A HN 2003000196 A HN2003000196 A HN 2003000196A HN 2003000196 A HN2003000196 A HN 2003000196A
Authority
HN
Honduras
Prior art keywords
indolinfenyl
sulfonamide derivatives
prophilaxiation
indolinfenylsulfonamide
dyssides
Prior art date
Application number
HN2003000196A
Other languages
English (en)
Inventor
Bischoff Hilmar
Dittrich Wengenroth Elke
Wuttke Martina
Heckroth Heike
Thielemann Wolfgang
Woltering Michael
Otteneder Michael
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HN2003000196A publication Critical patent/HN2003000196A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE A NUEVOS DERIVADOS SUSTITUIDOS DE INDOLINFENILSULFONAMIDA, A PROCEDIMIENTOS PARA SU PREPARACIÓN ASI COMO A SU USO EN MEDICAMENTOS.ESPECIALMENTE COMO POTENTES COMPUESTOS ACTIVADORES DE PPAR-DELTA, PARA LA PROFILAXIS Y/O EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, ESPECIALMENTE DE DISLIPIDEMIAS Y ENFERMEDADES CARDIACAS CORONARIAS.
HN2003000196A 2002-07-03 2003-07-02 Derivados de indolinfenilsulfonamida HN2003000196A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10229777A DE10229777A1 (de) 2002-07-03 2002-07-03 Indolin-Phenylsulfonamid-Derivate

Publications (1)

Publication Number Publication Date
HN2003000196A true HN2003000196A (es) 2004-11-22

Family

ID=29796112

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000196A HN2003000196A (es) 2002-07-03 2003-07-02 Derivados de indolinfenilsulfonamida

Country Status (26)

Country Link
US (1) US20060100230A1 (es)
EP (1) EP1519919A1 (es)
JP (1) JP2005535649A (es)
CN (1) CN1678581A (es)
AR (1) AR040352A1 (es)
AU (1) AU2003246638A1 (es)
BR (1) BR0312549A (es)
CA (1) CA2491477A1 (es)
DE (1) DE10229777A1 (es)
EC (1) ECSP055524A (es)
GT (1) GT200300135A (es)
HN (1) HN2003000196A (es)
HR (1) HRP20050108A2 (es)
IL (1) IL165924A0 (es)
MA (1) MA27316A1 (es)
MX (1) MXPA05000133A (es)
MY (1) MY134641A (es)
NO (1) NO20050579L (es)
NZ (1) NZ537486A (es)
PE (1) PE20040645A1 (es)
RU (1) RU2328485C2 (es)
TW (1) TW200418794A (es)
UA (1) UA79003C2 (es)
UY (1) UY27878A1 (es)
WO (1) WO2004005253A1 (es)
ZA (1) ZA200500013B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10335450A1 (de) * 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
DE10337839A1 (de) * 2003-08-18 2005-03-17 Bayer Healthcare Ag Indolin-Derivate
AR045582A1 (es) * 2003-09-05 2005-11-02 Neurogen Corp Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1
AR048523A1 (es) * 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
US7968723B2 (en) 2004-05-05 2011-06-28 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
CN101421258B (zh) * 2004-10-29 2013-08-21 凯利普西斯公司 作为ppar调节剂的磺酰基取代的双环化合物
ES2682282T3 (es) 2004-10-29 2018-09-19 Kalypsys, Inc. Compuestos bicíclicos sustituidos con sulfonilo como moduladores de PPAR
AU2006206682A1 (en) * 2005-01-18 2006-07-27 Novartis Ag Methods of use of dual PPAR agonist compounds and drug delivery devices containing such compounds
DE102005020230A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
DE102005020229A1 (de) * 2005-04-30 2006-11-09 Bayer Healthcare Ag Verwendung von Indolin-Phenylsulfonamid-Derivaten
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
EP2298742B1 (en) 2005-06-30 2014-01-08 High Point Pharmaceuticals, LLC phenoxy acetic acids as PPAR delta activators
FR2890072A1 (fr) * 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
EP2386540A1 (en) 2005-12-22 2011-11-16 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
TWI315304B (en) 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US8716317B2 (en) 2008-06-09 2014-05-06 Sanofi Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
BRPI0914978A2 (pt) 2008-06-09 2015-10-27 Sanofi Aventis sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos
JP5575137B2 (ja) 2008-10-22 2014-08-20 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病剤として有用な新規な環状ベンゾイミダゾール誘導体
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
PL2624696T3 (pl) 2010-10-06 2017-07-31 Glaxosmithkline Llc Pochodne benzimidazolu jako inhibitory kinazy PI3
CA2816753A1 (en) 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
US9394315B2 (en) 2012-05-08 2016-07-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP6192836B2 (ja) * 2013-07-30 2017-09-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒｃモジュレーターとしてのアザインドール化合物
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
WO2015095795A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
AU2015256190B2 (en) 2014-05-05 2019-08-15 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
US10221142B2 (en) 2015-02-11 2019-03-05 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としてのヘテロアリール置換安息香酸及びその使用
JP2018535958A (ja) 2015-10-27 2018-12-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
EP3368516B1 (en) 2015-10-27 2020-07-15 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
CN110483509B (zh) * 2019-09-04 2020-08-25 温州大学 一种合成含氮杂环衍生物的方法
CN110627785B (zh) * 2019-09-19 2021-06-25 温州大学 一种1,5-四氢萘啶衍生物的制备方法
US20230059009A1 (en) * 2019-12-18 2023-02-23 The Regents Of The University Of California Inhibitors of lin28 and methods of use thereof
EP4192957A4 (en) * 2020-08-07 2024-09-04 Casma Therapeutics Inc TRPML MODULATORS
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
KR100266467B1 (ko) * 1995-09-27 2000-10-02 우에노 도시오 설폰아미드 유도체
FR2757157B1 (fr) * 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2002014291A1 (en) * 2000-08-11 2002-02-21 Nippon Chemiphar Co.,Ltd. PPARδ ACTIVATORS

Also Published As

Publication number Publication date
MXPA05000133A (es) 2005-04-11
CA2491477A1 (en) 2004-01-15
MY134641A (en) 2007-12-31
US20060100230A1 (en) 2006-05-11
UY27878A1 (es) 2004-02-27
AR040352A1 (es) 2005-03-30
BR0312549A (pt) 2005-04-26
IL165924A0 (en) 2006-01-15
AU2003246638A1 (en) 2004-01-23
CN1678581A (zh) 2005-10-05
GT200300135A (es) 2004-03-17
UA79003C2 (en) 2007-05-10
TW200418794A (en) 2004-10-01
MA27316A1 (fr) 2005-05-02
JP2005535649A (ja) 2005-11-24
DE10229777A1 (de) 2004-01-29
WO2004005253A1 (de) 2004-01-15
PE20040645A1 (es) 2004-10-29
EP1519919A1 (de) 2005-04-06
NZ537486A (en) 2006-07-28
RU2328485C2 (ru) 2008-07-10
ZA200500013B (en) 2006-03-29
ECSP055524A (es) 2005-03-10
RU2005102592A (ru) 2005-07-10
HRP20050108A2 (hr) 2006-04-30
NO20050579L (no) 2005-02-02

Similar Documents

Publication Publication Date Title
HN2003000196A (es) Derivados de indolinfenilsulfonamida
HN1999000124A (es) Derivados de pirazol substituido.
CR7718A (es) Nuevos derivados de glicosido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
UY27720A1 (es) Aroilpiridinonas monocíclicas,
UY28122A1 (es) Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
ECSP077271A (es) Derivados de pirimidina
ECSP077259A (es) Derivados de pirimidina
ECSP077296A (es) Fenilaminotiazoles sustituidos y su uso
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
CR10778A (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiaxol-5-ona, procedimientos para su preparacion y su uso como agentes farmaceuticos
NI200800217A (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos.
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
AR055319A1 (es) Derivados de isoquinoleina, composiciones farmaceuticas y usos
HN2004000146A (es) Dihidroquinazolinas sustituidas
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
UY28253A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparación, medicamentos que comprenden este compuesto y su uso.
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
SV2004001294A (es) Derivados de acido acetico ref. lea 35699-sv
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
ECSP077306A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparación y su uso como antiinflamatorios
UY26951A1 (es) Derivados de ácido propiónico
HN2003000104A (es) Derivados de ciclopenteno
SV2006002290A (es) Nonadepsipeptidos acilados ii ref. bhc041327-sv